|
Cognition Disorders
|
0.400 |
Biomarker
|
group |
BEFREE |
Intraperitoneal Administration of Monoclonal Antibody Against Pathologic Aβ42 Aggregates Alleviated Cognitive Deficits and Synaptic Lesions in APP/PS1 Mice.
|
31839610 |
2020 |
|
Cognition Disorders
|
0.400 |
Biomarker
|
group |
BEFREE |
Notopterygium incisum extract (NRE) rescues cognitive deficits in APP/PS1 Alzhneimer's disease mice by attenuating amyloid-beta, tau, and neuroinflammation pathology.
|
31783135 |
2020 |
|
Cognition Disorders
|
0.400 |
Biomarker
|
group |
BEFREE |
Our results showed that tan IIA significantly ameliorates cognitive deficits and improves spatial learning ability of APP/PS1 mice in the nest-building test, novel object recognition test and Morris water maze test.
|
31778727 |
2020 |
|
Cognition Disorders
|
0.400 |
Biomarker
|
group |
BEFREE |
Fructooligosaccharides Ameliorating Cognitive Deficits and Neurodegeneration in APP/PS1 Transgenic Mice through Modulating Gut Microbiota.
|
30816709 |
2019 |
|
Cognition Disorders
|
0.400 |
Biomarker
|
group |
BEFREE |
Long-term icariin treatment ameliorates cognitive deficits via CD4<sup>+</sup> T cell-mediated immuno-inflammatory responses in APP/PS1 mice.
|
31190768 |
2019 |
|
Cognition Disorders
|
0.400 |
Biomarker
|
group |
BEFREE |
Rescue of cognitive deficits in APP/PS1 mice by accelerating the aggregation of β-amyloid peptide.
|
31847879 |
2019 |
|
Cognition Disorders
|
0.400 |
Biomarker
|
group |
BEFREE |
No significant difference was found between the APP/PS2 and wild-type mice at 2-6 months of age in terms of novel object recognition memory; subsequently, however, APP/PS2 mice showed a clear cognitive deficit at 12 months of age.
|
30047036 |
2019 |
|
Cognition Disorders
|
0.400 |
Biomarker
|
group |
BEFREE |
Cystatin isolated from chicken egg white, called ovocystatin, has been widely used in the medical and pharmaceutical research due to its structural and biological similarities to human cystatin C. The aim of this study was to assess the effect of administering ovocystatin on the development of dementia-specific cognitive deficits in APP/PS1 transgenic mice.
|
30504006 |
2019 |
|
Cognition Disorders
|
0.400 |
Biomarker
|
group |
BEFREE |
MicroRNA-181a protects against pericyte apoptosis via directly targeting FOXO1: implication for ameliorated cognitive deficits in APP/PS1 mice.
|
31467256 |
2019 |
|
Cognition Disorders
|
0.400 |
Biomarker
|
group |
BEFREE |
Our results indicate that NTP reduces neuroinflammation and improves the cognitive deficits in APP/PS1 mice possibly via BDNF/NF-κB pathway.
|
30972181 |
2019 |
|
Cognition Disorders
|
0.400 |
AlteredExpression
|
group |
BEFREE |
A Morris water maze test was performed and showed that overexpression of miR-361-3p improved cognitive deficits in APP/PS1 mice.
|
31601077 |
2019 |
|
Cognition Disorders
|
0.400 |
GeneticVariation
|
group |
BEFREE |
Our data also indicate that introduction of the Swedish mutation alone in endogenous APP is not sufficient to produce either AD-related brain pathology or cognitive deficits in mice.
|
30894120 |
2019 |
|
Cognition Disorders
|
0.400 |
AlteredExpression
|
group |
BEFREE |
At 9 months of age, untreated 3×Tg-AD mice vs. wild-type (WT) controls displayed cognitive deficits in behavioral assays and, at 12 months, elevated levels of hippocampal amyloid beta-protein (Aβ), amyloid precursor protein (APP), tau phosphorylation, and pro-inflammatory cytokines.
|
31603034 |
2019 |
|
Cognition Disorders
|
0.400 |
Biomarker
|
group |
BEFREE |
As a result, the nanochaperone reduces Aβ burden, attenuates Aβ-induced inflammation, and eventually rescues the cognitive deficits of APP/PS1 transgenic AD mice.
|
31763156 |
2019 |
|
Cognition Disorders
|
0.400 |
Biomarker
|
group |
BEFREE |
Taken together, our findings show that the TIPE2 expression level was negatively correlated with the pathogenesis of Alzheimer's disease, and overexpression of TIPE2 attenuates cognitive deficits in APP/PS1 mice, suggesting TIPE2 is a potential target for pharmacological intervention and improvement of cognitive deficits.Graphical Abstract .
|
31286344 |
2019 |
|
Cognition Disorders
|
0.400 |
Biomarker
|
group |
BEFREE |
DL0410 ameliorates cognitive deficits in APP/PS1 transgenic mice by promoting synaptic transmission and reducing neuronal loss.
|
31685977 |
2019 |
|
Cognition Disorders
|
0.400 |
Biomarker
|
group |
BEFREE |
In behavioral studies, SAR502250 improved the cognitive deficit in aged transgenic APP(SW)/Tau(VLW) mice or in adult mice after infusion of Aβ<sub>25-35</sub>.
|
31792284 |
2019 |
|
Cognition Disorders
|
0.400 |
GeneticVariation
|
group |
BEFREE |
Surprisingly, humanized APP knock-in mouse models carrying a single APP Swedish mutation (AppNL), failed to develop amyloid plaque aggregation or cognitive deficits.
|
30320577 |
2018 |
|
Cognition Disorders
|
0.400 |
Biomarker
|
group |
BEFREE |
Our previous study indicates that oral supplementation of taurine at 1000 mg/kg/day significantly ameliorates hippocampal-dependent cognitive deficits in APP/PS1 transgenic AD mouse model.
|
28849459 |
2018 |
|
Cognition Disorders
|
0.400 |
Biomarker
|
group |
BEFREE |
In this study, polyprenols were firstly evaluated the effects on the cognitive deficits and neuropathology in APP/PS1 mice model of AD.
|
29468792 |
2018 |
|
Cognition Disorders
|
0.400 |
AlteredExpression
|
group |
BEFREE |
By using biochemical and electrophysiological measures, we found that in a presymptomatic phase, when amyloid plaques have not yet formed and there is no sign of cognitive deficits, the over-expression of full-length APP in the hippocampus of Tg2576 mice altered membrane localization and inhibitory signalling activity of CB<sub>1</sub> receptor, possibly by binding to the receptor and reducing its specific interaction with caveolin-1 and G proteins.
|
29454025 |
2018 |
|
Cognition Disorders
|
0.400 |
Biomarker
|
group |
BEFREE |
These results indicated that L-NBP might stimulate the proliferation, migration, and differentiation of hippocampal neural stem cells and reversed cognitive deficits in APP/PS1 mice.
|
29728920 |
2018 |
|
Cognition Disorders
|
0.400 |
Biomarker
|
group |
BEFREE |
Naringin Dihydrochalcone Ameliorates Cognitive Deficits and Neuropathology in APP/PS1 Transgenic Mice.
|
29922152 |
2018 |
|
Cognition Disorders
|
0.400 |
Biomarker
|
group |
BEFREE |
Benfotiamine (BFT) rescued cognitive deficits and reduced Aβ burden in amyloid precursor protein (APP)/PS1 mice.
|
29860433 |
2018 |
|
Cognition Disorders
|
0.400 |
Biomarker
|
group |
BEFREE |
Here we report that the treatment of two animal tauopathy models (APP/PS1 and rTg4510) with Cu<sup>II</sup>(gtsm) recovers the cognitive deficits seen in both neurodegenerative models.
|
29920069 |
2018 |